CVRx Q4 revenue rises 4%, beats expectations

Reuters

14 hours ago

CVRx Q4 revenue rises 4%, beats expectations

Overview

Medical device company's Q4 revenue rose 4%, beating analyst expectations
Gross margin improved to 86% due to higher selling prices and efficiencies

Outlook

CVRx expects 2026 revenue between $63.0 mln and $67.0 mln
Company anticipates 2026 gross margin between 84% and 86%
CVRx forecasts Q1 2026 revenue between $13.7 mln and $14.7 mln

Result Drivers

SALES TERRITORY EXPANSION - Revenue growth driven by expansion into new sales territories and increased awareness of Barostim therapy
MANUFACTURING EFFICIENCIES - Improved manufacturing efficiencies contributed to higher gross margin

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Revenue	Beat	$16.02 mln	$15.82 mln (7 Analysts)
Q4 EPS		-$0.46
Q4 Net Income		-$11.93 mln
Q4 Gross Margin		86.00%
Q4 Basic EPS		-$0.46
Q4 Gross Profit		$13.83 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for CVRx Inc is $12.00, about 97.4% above its February 11 closing price of $6.08

Press Release: ID:nGNX46fsB3

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2611997096"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2611997096\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2611997096?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 05:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611997096","market":"fut","top_or_hot":-1,"title":"CVRx Q4 revenue rises 4%, beats expectations","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>CVRx Q4 revenue rises 4%, beats expectations</title></head><body><p><span>Overview</span></p><ul><li><p>Medical device company's Q4 revenue rose 4%, beating analyst expectations</p></li><li><p>Gross margin improved to 86% due to higher selling prices and efficiencies</p></li></ul><p><span>Outlook</span></p><ul><li><p>CVRx expects 2026 revenue between $63.0 mln and $67.0 mln</p></li><li><p>Company anticipates 2026 gross margin between 84% and 86%</p></li><li><p>CVRx forecasts Q1 2026 revenue between $13.7 mln and $14.7 mln</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>SALES TERRITORY EXPANSION - Revenue growth driven by expansion into new sales territories and increased awareness of Barostim therapy</p></li><li><p>MANUFACTURING EFFICIENCIES - Improved manufacturing efficiencies contributed to higher gross margin</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Beat</p></td><td><p>$16.02 mln</p></td><td><p>$15.82 mln (7 Analysts)</p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-$0.46</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$11.93 mln</p></td><td></td></tr><tr><td><p>Q4 Gross Margin</p></td><td></td><td><p>86.00%</p></td><td></td></tr><tr><td><p>Q4 Basic EPS</p></td><td></td><td><p>-$0.46</p></td><td></td></tr><tr><td><p>Q4 Gross Profit</p></td><td></td><td><p>$13.83 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", no \"hold\" and 1 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for CVRx Inc is $12.00, about 97.4% above its February 11 closing price of $6.08</p></li></ul><p>Press Release: <span>ID:nGNX46fsB3</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CVRx Q4 revenue rises 4%, beats expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCVRx Q4 revenue rises 4%, beats expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-13 05:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>CVRx Q4 revenue rises 4%, beats expectations</title></head><body><p><span>Overview</span></p><ul><li><p>Medical device company's Q4 revenue rose 4%, beating analyst expectations</p></li><li><p>Gross margin improved to 86% due to higher selling prices and efficiencies</p></li></ul><p><span>Outlook</span></p><ul><li><p>CVRx expects 2026 revenue between $63.0 mln and $67.0 mln</p></li><li><p>Company anticipates 2026 gross margin between 84% and 86%</p></li><li><p>CVRx forecasts Q1 2026 revenue between $13.7 mln and $14.7 mln</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>SALES TERRITORY EXPANSION - Revenue growth driven by expansion into new sales territories and increased awareness of Barostim therapy</p></li><li><p>MANUFACTURING EFFICIENCIES - Improved manufacturing efficiencies contributed to higher gross margin</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Beat</p></td><td><p>$16.02 mln</p></td><td><p>$15.82 mln (7 Analysts)</p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-$0.46</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$11.93 mln</p></td><td></td></tr><tr><td><p>Q4 Gross Margin</p></td><td></td><td><p>86.00%</p></td><td></td></tr><tr><td><p>Q4 Basic EPS</p></td><td></td><td><p>-$0.46</p></td><td></td></tr><tr><td><p>Q4 Gross Profit</p></td><td></td><td><p>$13.83 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", no \"hold\" and 1 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for CVRx Inc is $12.00, about 97.4% above its February 11 closing price of $6.08</p></li></ul><p>Press Release: <span>ID:nGNX46fsB3</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nL1N3Z81GW:1","article_id":"2611997096","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2611997096","pubTimestamp":1770930829,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CVRx Q4 revenue rises 4%, beats expectationsOverviewMedical device company's Q4 revenue rose 4%, beating analyst expectationsGross margin improved to 86% due to higher selling prices and efficienciesO","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","CVRX":"CVRx, Inc.","BK4539":"次新股"},"translate_title":"CVRx第四季度收入增长4%，超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CVRX":0.9},"content_text":"CVRx Q4 revenue rises 4%, beats expectationsOverviewMedical device company's Q4 revenue rose 4%, beating analyst expectationsGross margin improved to 86% due to higher selling prices and efficienciesOutlookCVRx expects 2026 revenue between $63.0 mln and $67.0 mlnCompany anticipates 2026 gross margin between 84% and 86%CVRx forecasts Q1 2026 revenue between $13.7 mln and $14.7 mlnResult DriversSALES TERRITORY EXPANSION - Revenue growth driven by expansion into new sales territories and increased awareness of Barostim therapyMANUFACTURING EFFICIENCIES - Improved manufacturing efficiencies contributed to higher gross marginKey DetailsMetricBeat/MissActualConsensus EstimateQ4 RevenueBeat$16.02 mln$15.82 mln (7 Analysts)Q4 EPS-$0.46Q4 Net Income-$11.93 mlnQ4 Gross Margin86.00%Q4 Basic EPS-$0.46Q4 Gross Profit$13.83 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", no \"hold\" and 1 \"sell\" or \"strong sell\"The average consensus recommendation for the medical equipment, supplies & distribution peer group is \"buy\"Wall Street's median 12-month price target for CVRx Inc is $12.00, about 97.4% above its February 11 closing price of $6.08Press Release: ID:nGNX46fsB3For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}